医学
中性粒细胞与淋巴细胞比率
肝细胞癌
内科学
胃肠病学
射频消融术
单变量分析
多元分析
临床意义
淋巴细胞
总体生存率
肿瘤科
烧蚀
作者
ZiHao Ni,Bolin Wu,Zhao Liu,Qiu-Cheng Wang,Xue Han,Wen Cheng,Cun-Li Guo
出处
期刊:British Journal of Radiology
[British Institute of Radiology]
日期:2023-04-01
卷期号:96 (1145)
摘要
Objective: Previous studies focused on the prognostic significance of the pre- or post-operative neutrophil–lymphocyte ratio (NLR); the significance of combined pre- and post-operative NLR (PP-NLR) remains unknown. Therefore, we investigated the value of PP-NLR for predicting prognosis after radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) to improve treatment and prolong survival. Methods: We investigated pre- and post-operative NLR and PP-NLR in predicting prognosis after RFA in patients with HCC. Optimal thresholds for leukocytes, lymphocytes, neutrophils, and NLR before and after RFA were retrospectively assessed in patients with HCC who had undergone RFA between January 2018 and June 2019 in Harbin Medical University Cancer Hospital. Risk factors for early HCC recurrence and those affecting recurrence-free survival (RFS) were analyzed. Results: The respective pre- and post-operative optimal thresholds were as follows: neutrophils, 3.431 and 4.975; leukocytes, 5.575 and 6.61; lymphocytes, 1.455 and 1.025; and NLR, 1.53 and 4.36. Univariate analysis revealed tumor number; alpha-fetoprotein level; post-operative leukocytes, lymphocytes, NLR, and neutrophils; pre-operative neutrophils and NLR; and PP-NLR as factors influencing early recurrence and RFS. Multivariate analysis indicated PP-NLR as an independent risk factor for poor RFS and early recurrence. Conclusion: PP-NLR was more effective for predicting prognosis than pre- or post-operative NLR alone for patients with HCC. Advances in knowledge: The novelty of this study lies in the combination of pre- and post-operative NLR, namely PP-NLR, to study its prognostic value for HCC patients after RFA, which has not been found in previous studies. The contribution of our study is that PP-NLR can provide clinicians with a new reference index to judge the prognosis of patients and make timely treatment to help patients improve their prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI